ENBREL (Immunex Corporation)
Welcome to the PulseAid listing for the ENBREL drug offered from Immunex Corporation. This Tumor Necrosis Factor Blocker [EPC],Tumor Necrosis Factor Receptor Blocking Activity [MoA] pharmaceutical is classified as a HUMAN PRESCRIPTION DRUG. Below, you can view details for this drug, such as its dosage form, route of delivery, start market/end market dates, and more. We have also randomly listed additional pharmaceuticals used in the same HUMAN PRESCRIPTION DRUG drug type category.
LABELER NAME / MANUFACTURER: | Immunex Corporation |
NON-PROPRIETARY NAME: | etanercept |
SUBSTANCE NAME: | ETANERCEPT |
TYPE: | HUMAN PRESCRIPTION DRUG |
PHARMA CLASS: | Tumor Necrosis Factor Blocker [EPC],Tumor Necrosis Factor Receptor Blocking Activity [MoA] |
ROUTE: | SUBCUTANEOUS |
DOSAGE FORM: | SOLUTION |
MARKETING CATEGORY NAME: | BLA |
START MARKETING DATE: | 2005-10-06 |
END MARKETING DATE: | 0000-00-00 |
ENBREL HUMAN PRESCRIPTION DRUG Details:
Item Description | ENBREL from Immunex Corporation |
LABELER NAME: | Immunex Corporation |
DEA SCHEDULE: |
|
ACTIVE STRENGTH: | 50(mg/mL) |
START MARKETING DATE: | 2005-10-06 |
END MARKETING DATE: | 0000-00-00 |
PRODUCT ID: | 58406-435_93b2cc40-ee24-4caf-8806-5b2b49b2bae4 |
PRODUCT NDC: | 58406-435 |
APPLICATION NUMBER: | BLA103795 |
Other ETANERCEPT Pharmaceutical Manufacturers / Labelers: